NCT06597565 2025-10-20
A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
H. Lee Moffitt Cancer Center and Research Institute
Eli Lilly and Company
Eli Lilly and Company